Zynyz (retifanlimab)
Research Synopsis
- Retifanlimab, marketed as Zynyz, is a PD-1 inhibitor that has recently been investigated for its efficacy in various cancers, including squamous cell carcinoma of the anal canal and Merkel cell carcinoma.
- Recent studies such as POD1UM-202 indicated a modest overall response rate of 13.8% in patients with advanced anal carcinoma post-chemotherapy, suggesting some anti-tumor activity.
- The POD1UM-303 study is assessing the combination of retifanlimab with carboplatin-paclitaxel, aiming to improve outcomes for patients with inoperable anal carcinoma.
- Retifanlimab also demonstrated promising results in MAHOGANY, a study on HER2+ gastric cancer, achieving a 53% objective response rate with a combination of margetuximab.
- The drug received accelerated approval for treating metastatic or recurrent Merkel cell carcinoma, showcasing its potential in aggressive skin cancers.
- Clinical trials indicate a manageable safety profile, although side effects such as lichenoid reactions and secondary adrenocortical insufficiency have been reported.
- Some studies found durable anti-tumor responses in solid tumors, with overall response rates varying from 23.5% to 40% in different cancer types during ongoing trials.
- The findings support further exploration of retifanlimab in conjunction with standard therapies to enhance treatment efficacy in hard-to-treat cancers.
- Overall, retifanlimab is showing potential as a valuable addition to the immunotherapy landscape, particularly for cancers resistant to conventional treatments.
Zynyz (retifanlimab)
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
London, UK
2 hours ago
1 Received
- - The standard treatment for advanced HER2+ gastric and gastroesophageal junction adenocarcinoma combines chemotherapy with trastuzumab, which targets the HER2 protein.
- - The MAHOGANY trial investigates new therapies: margetuximab (an optimized version of trastuzumab) combined with retifanlimab (which blocks PD-1) and tebotelimab (which targets both PD-1 and another immune checkpoint).
- - The trial aims to assess how effective and safe these combinations are compared to standard therapy, focusing on outcomes like response rate and overall survival.
$100 - $150
Hourly Rate
Emerging and Experimental Agents for Anal Cancer: What is New?
London, UK
2 hours ago
1 Received
- Squamous cell carcinoma of the anal canal (SCCA) is on the rise in the US, linked to HPV, and while it's responsive to chemoradiotherapy, many patients with advanced disease experience recurrence, leading to difficult treatment options.
- Current palliative chemotherapy for metastatic or unresectable SCCA has poor outcomes, highlighting the urgent need for more effective therapies.
- Promising advances in immunotherapy, including immune checkpoint inhibitors and novel technologies like bispecific antibodies, are currently being explored in clinical trials, which could significantly improve treatment strategies for SCCA in the near future.
$100 - $150
Hourly Rate
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).
London, UK
2 hours ago
1 Received
- A phase II study (POD1UM-202) evaluated the effectiveness of retifanlimab, a PD-1 targeting antibody, in patients with advanced or metastatic squamous carcinoma of the anal canal (SCAC) who had previously undergone platinum-based chemotherapy.
- * In the study involving 94 patients, the overall response rate was 13.8%, with one complete response and 12 partial responses, showing efficacy regardless of HIV/HPV status or PD-L1 expression.
- * Median progression-free survival was 2.3 months, and overall survival was 10.1 months, indicating that retifanlimab has meaningful antitumor activity and an acceptable safety profile in this hard-to-treat patient population.
$100 - $150
Hourly Rate
POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma.
London, UK
2 hours ago
1 Received
- Squamous carcinoma of the anal canal (SCAC) is an HPV-related cancer that often has a poor prognosis, especially in advanced stages, and standard treatment involves carboplatin-paclitaxel with a median survival of about 20 months.
- * An investigational drug, retifanlimab, which targets PD-1, has shown promise in improving outcomes for patients with advanced SCAC who have not responded to initial chemotherapy.
- * A new phase III study, POD1UM-303/InterAACT 2, aims to evaluate the effectiveness of adding retifanlimab to the existing treatment regimen for patients with inoperable SCAC who haven't received systemic chemotherapy.
$100 - $150
Hourly Rate
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
London, UK
2 hours ago
1 Received
- The study focused on patients with HER2-positive metastatic gastric and gastroesophageal adenocarcinoma, exploring a new treatment option combining margetuximab (an engineered antibody) and retifanlimab (an antibody targeting PD-L1) instead of traditional chemotherapy.
- In the trial involving 43 patients, the treatment resulted in a 53% objective response rate and a 73% disease control rate, with manageable adverse events reported, indicating promising effectiveness without significant toxicity.
- However, the study was discontinued early due to advancements in GEA treatments suggesting that the initial study design would not meet the requirements for drug approval.
$100 - $150
Hourly Rate
Cutaneous, oral and genital lichenoid reactions associated with retifanlimab, a new PD-1 inhibitor.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
In brief: Retifanlimab (Zynyz) for Merkel cell carcinoma.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Retifanlimab: First Approval.
London, UK
2 hours ago
1 Received
- - Retifanlimab (ZYNYZ) is a monoclonal antibody targeting the programmed cell death 1 (PD-1) receptor, developed by Incyte Corporation for treating solid tumors.
- - It has recently gained accelerated approval for treating adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
- - The article outlines the key milestones in retifanlimab's development process that led to its first approval for this specific type of cancer.
$100 - $150
Hourly Rate
Retifanlimab-dlwr.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Antibodies to watch in 2024.
London, UK
2 hours ago
1 Received
- The 'Antibodies to Watch' series gives an annual overview of monoclonal antibody therapeutics that are either in late-stage development, undergoing regulatory review, or have recently been approved, focusing on 16 antibodies granted approval in 2023.
- It also highlights nearly 50 additional product candidates that are either awaiting approval or expected to enter review by the end of 2024, featuring innovative types like bispecific antibodies and antibody-drug conjugates.
- Finally, the article discusses the clinical approval success rates of these antibody therapeutics, which range from 14-32%, indicating that the biopharmaceutical industry is actively advancing and finding success in developing these treatments, especially for non-cancer conditions.
$100 - $150
Hourly Rate
A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
London, UK
2 hours ago
1 Received
- The POD1UM-203 study tested retifanlimab, a monoclonal antibody that targets PD-1, on patients with specific solid tumors that have had successful responses to immune checkpoint therapies in the past.
- A total of 121 patients with various cancers (melanoma, NSCLC, urothelial carcinoma, and renal cell carcinoma) were treated, showing overall response rates ranging from 23.5% to 40% across different cohorts.
- Results indicate that retifanlimab has durable anti-tumor effects and a safety profile similar to other PD-(L)1 inhibitors, supporting further investigation in solid tumors.
$100 - $150
Hourly Rate
A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
London, UK
2 hours ago
1 Received
- Retifanlimab is a monoclonal antibody targeting PD-1, undergoing a phase I study to assess its safety and optimal dosing for patients with advanced solid tumors.
- The study had two parts: dose escalation with varying doses of retifanlimab and a cohort expansion for specific tumor types like endometrial and non-small-cell lung cancer (NSCLC), focusing on safety and efficacy.
- Results showed no dose-limiting toxicities, with a selected expansion dose of 3 mg/kg every 2 weeks, but only a modest objective response rate (up to 20%) in tumor-specific cohorts, alongside significant immune-related adverse events in some patients.
$100 - $150
Hourly Rate
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
London, UK
2 hours ago
1 Received
- The study investigates the combination of the modified docetaxel, cisplatin, and fluorouracil (mDCF) regimen with atezolizumab as a first-line treatment for advanced squamous cell carcinoma of the anus, building on mDCF’s established efficacy.
- Conducted across 21 centers in France, the phase 2 study randomly assigned participants to receive either the combination therapy or mDCF alone, focusing on 12-month progression-free survival as the primary endpoint.
- With 97 participants enrolled, the study found a median follow-up of 26.5 months, providing valuable insights into the potential benefits of combining immunotherapy with standard chemotherapy.
$100 - $150
Hourly Rate
PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.
London, UK
2 hours ago
1 Received
- The study evaluated the safety and efficacy of retifanlimab (a monoclonal antibody) and INCB001158 (an oral arginase inhibitor) in Japanese patients with advanced solid tumors through a phase Ib trial.
- Eighteen patients participated, with no dose-limiting toxicities or severe adverse events; common treatment-related issues included mild rash and one immune-related thyroid disorder.
- Results showed some antitumor activity with retifanlimab monotherapy (33.3% overall response rate), but the combination therapy did not yield any positive responses, indicating further research is needed.
$100 - $150
Hourly Rate
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study.
London, UK
2 hours ago
1 Received
- Advanced penile squamous cell carcinoma (PSCC) has poor outcomes, and patients often have limited treatment options, but PD-L1 expression is a potential target for immunotherapy, like retifanlimab.
- In the ORPHEUS trial, 18 previously untreated patients received retifanlimab, showing an objective response rate of 16.7% and a median duration of response of 3.3 months, with some patients experiencing clinical benefit.
- The results indicate that retifanlimab has potential activity against advanced PSCC with manageable safety, but the small sample size suggests the need for further studies to confirm these findings.
$100 - $150
Hourly Rate
Secondary adrenocortical insufficiency after treatment with retifanlimab: a case report.
London, UK
2 hours ago
1 Received
- Immune checkpoint inhibitors (ICIs) are becoming the primary treatment for various cancers but can cause immune-related adverse events (irAEs) that raise clinical concerns.
- A case study highlights a 73-year-old female with endometrial cancer who developed secondary adrenocortical insufficiency (AI) after receiving PD-1 treatment, leading to several symptoms including nausea and electrolyte imbalances.
- The patient's symptoms improved rapidly with glucocorticoid treatment, emphasizing the need for thorough endocrine evaluations in immunotherapy patients presenting with gastrointestinal issues.
$100 - $150
Hourly Rate
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates.
London, UK
2 hours ago
1 Received
- Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer linked to the Merkel cell polyomavirus or ultraviolet (UV) exposure, which increases immune system recognition due to viral proteins or neoantigens.
- Historical treatments for advanced MCC were limited to conventional chemotherapy, offering a short median response duration of about 3 months.
- Since 2017, immune checkpoint inhibitors like avelumab, pembrolizumab, and nivolumab have shown promising results, with immunotherapy providing comparable or better response rates than chemotherapy, particularly nivolumab in the adjuvant setting.
$100 - $150
Hourly Rate
Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study.
London, UK
2 hours ago
1 Received
- Retifanlimab, a monoclonal antibody targeting programmed death 1, is being tested for safety and effectiveness in patients with recurrent microsatellite instability-high/mismatch repair deficient endometrial cancer.
- In a study involving 76 patients, half experienced significant side effects, with anemia and fatigue being the most common, but many also achieved positive treatment responses.
- The results indicate that retifanlimab is generally well tolerated and shows promising anti-tumor activity, with some patients having a progression-free survival of over a year.
$100 - $150
Hourly Rate
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies.
London, UK
2 hours ago
1 Received
- - Pemigatinib, a selective FGFR inhibitor, was evaluated in the FIGHT-101 study, which explored its safety and effectiveness in patients with advanced solid tumors, particularly those with FGFR alterations, through various treatment combinations.
- - Patients received different doses of pemigatinib in combination with drugs like gemcitabine, cisplatin, and pembrolizumab, with key focus on safety, tumor response rates, and pharmacokinetics, resulting in varying levels of treatment-emergent adverse events.
- - The study showed objective response rates (ORRs) ranging from 0% to 37.5% across different combinations, with some patients experiencing tumor shrinkage, and noted that patients with
$100 - $150
Hourly Rate
Updates in the Management of Advanced Nonmelanoma Skin Cancer.
London, UK
2 hours ago
1 Received
- For locally advanced, clinically node-negative cSCCs and MCCs, sentinel node biopsy is recommended to assess cancer spread.
- Patients with BCC who do not respond to traditional treatments may benefit from hedgehog inhibitors, while immune checkpoint inhibitors like cemiplimab and pembrolizumab are options for those with advanced or recurrent forms of the cancers. *
$100 - $150
Hourly Rate